Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

Former Horizon chief Darrin Disley to lead the company through series A round

Eli Lilly HQ

Lilly, Pfizer say NGF drug works in back pain too

Tanezumab was able to show a statistically significant improvement in pain

- PMLiVE

Intercept NASH drug closes in on FDA approval

Although the drug failed to meet secondary endpoint

- PMLiVE

As government rushes through no-deal legislation, UK biotech repeats Brexit plea

UK market would be relegated in importance

Cell and gene therapy

Tackling the manufacturing cost and complexity challenges

- PMLiVE

Forster Communications and Cello Health launch sustainability service

New programme will drive innovation culture and enhance reputations

- PMLiVE

Excellent teamwork and interdepartmental collaboration lead to double promotion at Porterhouse Medical

Porterhouse Medical is thrilled to announce two further promotions within our scientific and client services teams this month, and would like to congratulate the delightful duo, Alice Wright and Rose Rickman.Alice has been...

Porterhouse Medical Group

- PMLiVE

New ‘NHSX’ unit will lead health service digital transformation

Will bring together public and private sector to accelerate change

- PMLiVE

Gyroscope’s gene therapy given to first dry AMD patient

Nearly 200m people worldwide have condition

- PMLiVE

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

CNS penetration could give edge over rival

- PMLiVE

‘Inflexible’ NICE blocking access to rare disease drugs

Spinraza most high profile example of access problem

- PMLiVE

2019: CRISPR and therapeutic gene editing comes of age

Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links